- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - FDA approves Tagrisso for 1st-line use in NSCLC
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
AnnouncementREG - AstraZeneca PLC - AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Lokelma approved in the EU
AnnouncementREG - AstraZeneca PLC - ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
AnnouncementREG - AstraZeneca PLC - Annual Financial Report
AnnouncementREG - AstraZeneca PLC - Total Voting Rights <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Lynparza CHMP for ovarian cancer maintainance <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AstraZeneca's IMFINZI approved for Stage III nsclc <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Selumetinib in NF1 gets FDA orphan drug status <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZN: Full-Year 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 5
AnnouncementREG - AstraZeneca PLC - AZN: Full-Year 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 4
Announcement